Endogenous Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy.

Xiaohong ZhengXia ZhouGang MaJiahao YuMiao ZhangChunmei YangYinan HuShuoyi MaZheyi HanWen NingBoquan JinXinmin ZhouJingbo WangYing Han

Published in: Stem cell research & therapy (2022)

Our data suggest that FSTL1 facilitates the immunosuppression of MSCs on macrophages and that guarantee the anti-fibrotic effect of MSCs in liver fibrosis.

Keyphrases

mesenchymal stem cells
liver fibrosis
umbilical cord
systemic sclerosis
idiopathic pulmonary fibrosis
bone marrow
cell therapy
electronic health record
big data